Patent · US Active

Slit2D2-chimeric antigen receptor and application thereof

US11246888B2 · kind B2 · utility

0Cited by

3References

8Claims

0Family size

Assignee

ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD. · CN

Inventors

Huashun Li · Suzhou, CN
Baolei Wang · 红钢城街道, CN
Baoyong Ren · Suzhou, CN

Key dates

Filing date	Oct 15, 2018
Grant date	Feb 15, 2022
Priority date	—
Expiry date	Apr 26, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16043
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A chimeric antigen receptor (CAR) and a gene encoding the CAR. The CAR comprises an extracellular domain capable of binding to an antigen, a transmembrane domain, and intracellular immune co-stimulatory molecule, wherein the extracellular domain comprises a D2 domain of a Slit2 protein. A chimeric antibody-expressing cell, which introduces a gene encoding the CAR into a cell so as to express the CAR on the surface of the cell. The CAR or CAR-expressing cell can be used as a cell drug for the treatment of tumor diseases. By using the CAR for engineering cells, especially T cells, the engineered T cells can specifically recognize and kill tumors, and have higher tumoricidal activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.